Morepen Laboratories Q2 FY27 Results: Consolidated Net Profit ₹88.89 Crore on Total Income of ₹755 Crore
Earnings
Pharmaceuticals
Blacklitt Research3 min read
Morepen Laboratories (NSE: MOREPENLAB) reported consolidated total income of ₹755.19 crore and net profit of ₹88.89 crore for the quarter ended 30 Sep 2026, it said in a filing on 27 Oct 2026. Standalone total income was ₹686.43 crore and standalone net profit ₹77.87 crore.
Key highlights
Consolidated
Including its subsidiaries
Total income: ₹755.19 crore, up 81.4% YoY and 31.3% QoQ
Net profit and EPS: ₹88.89 crore, up 116.6% YoY; basic EPS ₹1.62 against ₹0.75 a year earlier
Finance costs: ₹5.19 crore, 0.7% of total income
Standalone
The company on its own, without its subsidiaries
Total income: ₹686.43 crore, up 83.5% YoY and 25.6% QoQ
Net profit and EPS: ₹77.87 crore, up 441.6% YoY; basic EPS ₹1.42 against ₹0.26 a year earlier
Finance costs: ₹5.10 crore, 0.7% of total income
Summary
Consolidated ₹ crore
Particulars
Q2 FY27
Q2 FY26
YoY
Q1 FY27
QoQ
755.19
416.21
+81.4%
575.31
+31.3%
Revenue from operations
746.50
411.58
+81.4%
570.13
+30.9%
Other income
8.69
4.64
+87.3%
5.18
+67.6%
88.89
41.04
+116.6%
56.35
+57.8%
Profit before tax
116.54
45.69
+155.0%
74.53
+56.4%
Finance costs
5.19
4.18
+24.2%
4.84
+7.3%
Depreciation
10.07
11.28
-10.7%
8.35
+20.6%
Tax expense
27.65
4.65
+494.4%
18.18
+52.1%
Net profit margin
11.77%
9.86%
+1.91 pp
9.79%
+1.98 pp
EPS, basic (₹)
1.62
0.75
+116.0%
1.03
+57.3%
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
Net profit grew faster than total income. Consolidated net profit rose 116.6% to ₹88.89 crore while total income rose 81.4%, and profit before tax rose 155.0% to ₹116.54 crore. Tax expense rose 494.4% to ₹27.65 crore, so the tax charge absorbed a larger share of profit before tax than in the year-ago quarter.
Other income is small against the operating line. Other income of ₹8.69 crore is 1.2% of consolidated total income and 7.5% of profit before tax. Finance costs of ₹5.19 crore are 0.7% of total income, up 24.2% YoY against revenue growth of 81.4%.
Depreciation fell 10.7% YoY to ₹10.07 crore, while it rose 20.6% from the previous quarter. The notes do not explain the year-ago exceptional item of ₹25.83 crore in the half year ended 30 Sep 2025, which is shown in the statement.
Standalone ₹ crore
Particulars
Q2 FY27
Q2 FY26
YoY
Q1 FY27
QoQ
686.43
374.18
+83.5%
546.35
+25.6%
Revenue from operations
678.00
369.53
+83.5%
541.04
+25.3%
Other income
8.43
4.65
+81.3%
5.31
+58.8%
77.87
14.38
+441.6%
54.00
+44.2%
Profit before tax
103.65
18.86
+449.5%
72.15
+43.7%
Finance costs
5.10
4.11
+24.3%
4.78
+6.8%
Depreciation
9.70
10.70
-9.4%
7.98
+21.5%
Tax expense
25.78
4.49
+474.6%
18.15
+42.0%
Net profit margin
11.34%
3.84%
+7.50 pp
9.88%
+1.46 pp
EPS, basic (₹)
1.42
0.26
+446.2%
0.99
+43.4%
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
Standalone profit moved further than the consolidated figure. Standalone net profit rose 441.6% to ₹77.87 crore on total income up 83.5%, and profit before tax rose 449.5% to ₹103.65 crore. The year-ago base was low: the year-ago quarter had profit before tax of ₹18.86 crore and tax of ₹4.49 crore.
The standalone statement shows a disposal group held for sale, with assets of ₹361.82 crore and liabilities of ₹131.97 crore as at 30 Sep 2026. The notes read do not say when the disposal is expected to complete.
Consolidated net profit of ₹88.89 crore is ₹11.02 crore higher than standalone net profit of ₹77.87 crore, a gap that the filing's figures show but do not break down.
The notes record a final dividend of ₹0.20 per equity share of face value ₹2.00, approved at the annual general meeting on 26 Sep 2026 and paid on 13 Oct 2026. The company says the Himachal Pradesh High Court, Shimla, quashed a show cause notice seeking recovery of ₹117.94 crore, and that a contingent liability of ₹317.37 crore as at 31 Mar 2026 no longer exists.
The auditors' limited review carried no modification. They did not review the interim results of five subsidiaries, which reflect total revenues of ₹265.11 crore before consolidation adjustments for the quarter.
Inference
The filing reports a final dividend paid in October 2026 and a favourable court order that removes a contingent liability of ₹317.37 crore. The filing does not say how the court order affects future provisions or cash flows.
The notes do not give a reason for the large rise in income and profit against the year-ago quarter, nor the nature of the year-ago exceptional item or the 2025 sale of subsidiary shares.
Create a free account to read the rest of this article and the analysis that follows.
By continuing you agree to our Terms and Privacy Policy, and to receive updates from Blacklitt by email. You can unsubscribe anytime.
Disclaimer:
The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.
MOREPENLABMorepen Laboratories Ltd.
